We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Indivior Plc | LSE:INDV | London | Ordinary Share | GB00BN4HT335 | ORD USD0.50 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-19.00 | -2.00% | 931.00 | 935.00 | 937.50 | 953.50 | 906.50 | 938.00 | 325,897 | 16:35:11 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.09B | 2M | 0.0154 | 607.79 | 1.23B |
Date | Subject | Author | Discuss |
---|---|---|---|
05/6/2023 08:01 | Underlying EPS was $0.41 in Q1, annualised this is EPS of £1.32 and puts these shares on a forward PE of just 12x... With sublocade growth averaging 12.5% a quarter over the last 6 quarters this looks far too cheap. Suspect it rerates to between 15-20x FY23 PE once on NASDAQ (£20-26) | 74tom | |
05/6/2023 07:25 | Good start! Now let’s build from there please | youngers | |
05/6/2023 06:36 | Hoping for a pop here this morning 🙏 | youngers | |
04/6/2023 21:32 | I'm sure that Indivior bust a gut to get a settlement over the line before the Nasdaq listing.You have to factor in that these sort of legal proceedings are endemic when it comes to holding a company like Indivior.Even Glaxo recently got cited in respect of Zantac,the drug that transformed the group back in the 1980s.There's always going to be some legal johnny,rightly or wrongly, in the wings looking to the main chance with these drug companies.It's a question of evaluating whether the ever present threat of litigation is discounted when assessing the company's trading prospects.Fairly impossible task unless you're clairvoyant!Every litigation episode takes a bit of bounce out of the bungee i suppose.So,i don't think a race back to £20 is likely short term but maybe high teens is possible if the US listing gets off to a good start. | steeplejack | |
03/6/2023 09:35 | Mm 42 plus US States might well require an awful lot of lawyers even to cover the field but the deal is done and for once well within estimates -so where’s the beef! Will see how the share price progresses now especially with the12June added listing | gregmorg | |
02/6/2023 18:32 | Interesting that a 100m settlement is in line with a 290m provision. That’s some bloody legal bill!! Only ones who ever wins are the lawyers | youngers | |
02/6/2023 18:13 | Brilliant news!! Back to £20 next week? | youngers | |
02/6/2023 17:24 | Great news tonight (I think). | dealy | |
30/5/2023 08:29 | Perhaps on our demise (hopefully not before)some of the more active private investors will be stuffed and exhibited in a museum.I will keep a wary eye out for roaming taxidermists. | steeplejack | |
27/5/2023 11:34 | I would say the death of the retail stock picker / investor is pretty much universal. Hardly anyone i know across many countries would even consider buying a single share (other than the uber caps like Apple).For most small and mid caps the only way to get a reasonable valuation is to sell the company, but that is an activity which is also in the doldrums. Dividends and buy backs can help but that requires profits and no nasties on the horizon | dealy | |
25/5/2023 08:33 | According to media coverage this AM ,Liontrust is favouring Indivior given that a major new competitor has delayed the launch of a rival product , presumably to Indivior's former premier product, the declining Suboxone film. As a consequence, group revenue, presumably this year, will be better than previously expected. Not sure which rival to suboxone this is but a little checking will, no doubt, reveal the detail. | gregmorg | |
24/5/2023 08:59 | Indivior to Commence Trading on Nasdaq Global Select Market in June 05/24/2023 | 04:17am BST (MT Newswires) -- Indivior (INDV.L) said Tuesday it expects to start the trading of its ordinary shares on the Nasdaq Global Select Market on June 12 under the ticker INDV. The pharmaceutical company will retain its premium listing on the London stock exchange and terminate its American depository receipt program, with the shares to be exchanged for Indivior shares on a 1:1 basis. The US listing remains subject to the approval of the Securities and Exchange Commission. Shares in Indivior were down more than 2% on Tuesday's close. Price (GBP): £1470.00, Change: £-31.00, Percent Change: -2.07% | maywillow | |
24/5/2023 08:56 | greg are you saying that overall shares volumes are falling I must admit i feel that there is little change but if you are right have those throwing in the towel have in main already sold and the other are holding on until super good news prevails As Always time will tell | maywillow | |
24/5/2023 08:42 | Mm, it sounds as if everyone is throwing in the towel on equity investing. Now where within market cycles has that happened in the past! Must dig up my notes! | gregmorg | |
24/5/2023 05:47 | Executives see the US as an environment that embraces higher growth, while they bemoan the lack of interest from UK-based investors in their home market, particularly pension funds that have increasingly shunned British stocks over the past two decades. “There are no domestic equity investors here — everything else is a symptom,” said Michael Tory, founder of advisory firm Ondra Partners. “It’s not about the listing rules, the governance or the free float requirements. Global investors look to domestic investors for the signal to validate the investment, and that local signal has simply flickered out.” | steeplejack | |
23/5/2023 21:27 | Google the decline in relation to pension funds and investment trusts. They still invest... but not in all the LSE has to offer | casholaa | |
23/5/2023 15:25 | Nahhhh opvee needs to go live | casholaa | |
23/5/2023 08:04 | This is great news. Surprised we’ve not seen a bigger impact today | youngers | |
23/5/2023 07:49 | Cream of the crop. | casholaa |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions